No abstract

Current available evidence suggests that preoperative administration of tranexamic acid is safe and may reduce intraoperative bleeding as well as postoperative eyelid edema and ecchymosis in patients undergoing rhinoplasty.

In this information epidemiology (infodemiology) study, we describe the online public interest about the issue of femicide in Brazil and analyze the relationship between search queries and femicide trends from 2004 to 2015. We showed that information-seeking behavior for femicide in the Brazilian states has been strongly influenced by female homicide rates. Educational and policy-related interventions are needed to improve the population's knowledge and attitude toward femicide.

No abstract

No abstract

<div class="WordSection1"><p><strong>Objective</strong>: This study evaluated changes in the esthetic perceptions of patients subjected to in-office tooth bleaching. <strong>Material</strong><em> </em><strong>and</strong><em> </em><strong>Methods</strong>: Fifty participants included in a clinical trial evaluating the in-office tooth bleaching answered two questionnaires about their dental esthetic perceptions. The participants answered the Orofacial Esthetic Scale (OES) questionnaire and the Psychosocial Impact of Dental Aesthetics Questionnaire (PIDAQ) before and after treatment. The average scores observed at baseline were compared with those recorded after tooth bleaching using the paired t-test or the Wilcoxon signed rank test (α = 0.05). <strong>Results</strong>: Improvement in tooth color (reduction of 5.1 shade guide units) had a positive impact on patients’ perceptions. According to PIDAQ, tooth bleaching significantly increased the psychological impact and dental self-confidence; and reduced esthetic concerns. The OES demonstrated improvements in participants’ satisfaction for all questions, except for the one on “facial appearance”. However, higher effect size was observed for the question related to tooth color, as expected. <strong>Conclusion</strong>: Tooth bleaching was associated with an overall improvement in dental esthetic perception, even when only tooth color was affected.</p><p><strong>Keywords</strong></p><p>Patient-reported outcomes; Randomized Controlled Clinical Trials; Tooth Bleaching.</p></div>

Purpose Nitazoxanide is a broad-spectrum antiparasitic that has been tested for COVID-19 due to its anti-inflammatory effects and in vitro antiviral activity. This study synthesized the best evidence on the efficacy and safety of nitazoxanide in COVID-19. Methods Searches for studies were performed in peer-reviewed and grey-literature from January 1, 2020 to May 23, 2022. The following elements were used to define eligibility criteria: (1) Population: individuals with COVID-19; (2) Intervention: nitazoxanide; (3) Comparison: placebo; (4) Outcomes: primary outcome was death, and secondary outcomes were viral load, positive RT-PCR status, serum biomarkers of inflammation, composite measure of disease progression (ICU admission or invasive mechanical ventilation), and any adverse events; (5) Study type: blinded, placebo-controlled, randomized clinical trials (RCTs). Treatment effects were reported as relative risk (RR) for dichotomous variables and standardized mean difference (SMD) for continuous variables with 95% confidence intervals (CI). Results Five blinded, placebo-controlled RCTs were included and enrolled individuals with mild or moderate SARS-CoV-2 infection. We found no difference between nitazoxanide and placebo in reducing viral load (SMD =  − 0.16; 95% CI − 0.38 to 0.05) and the frequency of positive RTP-PCR results (RR = 0.92; 95% CI 0.81 to 1.06). In addition, there was no decreased risk for disease progression (RR = 0.63; 95% CI 0.38 to 1.04) and death (RR = 0.81; 95% CI 0.36 to 1.78) among patients receiving nitazoxanide. Patients with COVID-19 treated with nitazoxanide had decreased levels of white blood cells (SMD =  − 0.15; 95% − 0.29 to − 0.02), lactate dehydrogenase (LDH) (SMD − 0.32; 95% − 0.52 to − 0.13), and D-dimer (SMD − 0.49; 95% CI − 0.68 to − 0.31) compared to placebo, but the magnitude of effect was considered small to moderate. Conclusion This systematic review showed no evidence of clinical benefits of the use of nitazoxanide to treat patients with mild or moderate COVID-19. In addition, we found a reduction in WBC, LDH, and D-dimer levels among nitazoxanide-treated patients, but the effect size was considered small to moderate. Supplementary Information The online version contains supplementary material available at 10.1007/s00228-022-03380-5.

Purpose: Nitazoxanide is a broad-spectrum antiparasitic that has been tested for COVID-19 due to its anti-inflammatory effects and in vitro antiviral activity. This study synthesized the best evidence on the efficacy and safety of nitazoxanide in COVID-19. Methods: Searches for studies were performed in peer-reviewed and grey-literature. The following elements were used to define eligibility criteria: (1) Population, individuals with COVID-19; (2) Intervention, nitazoxanide; (3) Comparison, placebo; (4) Outcomes: viral load, positive RT-PCR status, composite measure of disease progression (ICU admission or invasive mechanical ventilation), death, serum biomarkers of inflammation, and any adverse events; (5) Study type: blinded, placebo-controlled, randomized clinical trials (RCTs). Results: Five blinded, placebo-controlled RCTs were included and enrolled individuals with mild or moderate SARS-CoV-2 infection. We found no difference between nitazoxanide and placebo in reducing viral load and frequency of positive RTP-PCR results. In addition, there was no decreased risk for disease progression and death among patients receiving nitazoxanide. Patients with COVID-19 treated with nitazoxanide had decreased levels of white blood cells, lactate dehydrogenase, and D-dimer compared to placebo, but the magnitude of effect was considered small to moderate. Conclusion: Available evidence based on the results of blinded, placebo-controlled, RCTs showed no clinical benefits of nitazoxanide in COVID-19.